Careers

Intestine Cancer

After undergoing surgery and chemotherapy for colon cancer, combined cell therapy has achieved long-term stability

时间：2026-04-22　人气：

If you can't understand the subsequent professional descriptions, just take two minutes to read through this text

Overview of the disease

This is Mr. Yang's fourth disease evaluation. Previous content can be viewed by clicking the link below

First evaluation (December 31, 2021): A post-90s male with liver metastasis of colon cancer, besides chemotherapy, can also use this

Second evaluation (July 22, 2022): Don't panic when diagnosed with colon cancer, understand well before treatment, and avoid detours

Third evaluation (December 9, 2022): How did he treat advanced colon cancer?

The fourth evaluation revealed a mass in the descending colon and a liver lesion, suggesting metastasis. PET-CT scan showed thickening of the wall and narrowing of the lumen at the junction of the descending and sigmoid colon, with serosal invasion and lymph node metastasis. Colonoscopy revealed an ulcerative mass growing circumferentially, making it impossible to pass through. Pathology confirmed moderately differentiated adenocarcinoma. After being diagnosed with colon cancer, Mr. Yang underwent partial hepatectomy and radical resection of the sigmoid colon in June 2020. Postoperative pathology revealed moderately differentiated adenocarcinoma in the sigmoid colon, with invasion of the subserosal fibrous adipose tissue, visible vascular thrombi, and nerve invasion. Pericolic lymph nodes showed metastatic cancer (4/21), with cancer invading beyond the lymph node capsule. Liver tissue resected from S8 liver lesion also contained moderately differentiated adenocarcinoma, consistent with liver metastasis from colon cancer. No cancer was found at the resection margin. Tumor pathological staging was pT3N2aM1. Genetic testing identified KRAS mutation p.G12A and APC mutation. After surgery, Mr. Yang was found to have multiple small lymph nodes newly appearing in the mesentery. On July 6, 2020, the patient underwent chemotherapy with the XELOX regimen. Post-chemotherapy CT scan revealed multiple small lymph nodes in the mesentery, consistent with previous findings, indicating potential metastasis.

Dept.

small

Knowledge

knowledge

KRAS mutation

Colon cancer is a common malignant tumor, and KRAS gene mutation is one of the important factors in its occurrence and development. The KRAS gene encodes a GTPase that participates in the regulation of cell signaling pathways, and mutations can cause the KRAS protein to lose its normal regulatory function, thereby promoting uncontrolled cell proliferation and metastasis. KRAS mutations are common in colon cancer patients, accounting for about 40% of cases. Currently, KRAS mutations have become an important indicator in the treatment of colon cancer. For patients with positive KRAS mutations, conventional chemotherapy and radiotherapy have poor efficacy, and targeted therapy drugs under development may be effective, but they are still in the research stage. Therefore, it is very important for colon cancer patients to understand their KRAS gene status, which can provide important basis for the selection of treatment options.

Mr. Yang completed surgery and postoperative chemotherapy. However, due to the late detection, liver metastases had already occurred. Although a resection was performed, there may still be residual cancer cells in his body that cannot be detected. Mr. Yang is very worried about this. After extensive research, Mr. Yang and his family learned about Professor Zhang Minghui's vNKT technology at Tsinghua University School of Medicine through a friend's recommendation, and carefully reviewed the displayed cases of vNKT cell therapy. They particularly hope to try it to reduce the risk of tumor recurrence and delay the time of recurrence and metastasis.

After reviewing Mr. Yang's medical records, Professor Zhang Minghui made the following analysis and judgment:

1. The patient's tumor had already metastasized when it was discovered, indicating a late stage.

2. Colonic malignant tumors are quite special, and even if liver metastasis occurs, there is a chance for surgery. Radical surgery can be performed to remove both the primary and metastatic lesions, and the prognosis is better compared to other metastatic tumors.

3. Patients undergo radical surgery and postoperative chemotherapy, and the basic conventional treatment plan has been completed. However, many patients still have the risk of metastasis and recurrence even if the tumor cannot be completely eradicated through surgery and chemotherapy alone..

4. vNKT therapy uses powerful immune cells to kill tumor cells that may remain undetected in the body, and has almost no side effects. On the basis of completing routine treatment, vNKT therapy can effectively reduce the risk of tumor recurrence and delay the occurrence of recurrence/metastasis..

Mr. Yang decided to use vNKT cell immunotherapy in September 2020, with an initial regimen of 1 course/month.As of March 2023, 41 courses have been completed, and no significant progress has been observed during multiple follow-up examinations.

Image Aspects

Tumor markers

Month

CEA: Increased in May 2020, returned to normal range upon reexamination in June 2020, and no abnormalities were found in subsequent regular examinations;

CA19-9: Regular monitoring showed values within the normal range.

Conclusion and Comments

After adopting the vNKT cell therapy method, Mr. Yang achieved the expected results, and his quality of life improved significantly. He is in a very good mental state, feels more energetic than before, and has returned to his pre-illness state. His normal life and work have not been affected by the disease. After more than a year, the latest assessment result remains stable with no progression, and immunotherapy is considered to be one of the most promising directions in tumor treatment. Mr. Yang's case serves as a good illustration of this point. A retrospective study was conducted on 210 colon cancer patients, in which 36.7% were found to have KRAS mutations, and 76.5% of cases had KRAS exon 2 mutations. In addition, mutations in codon 12 are associated with a higher incidence of lymph node positivity and lead to lower overall survival rates< H441>[¹^]。

Mr. Yang had risk factors such asKRAS mutation and vascular cancer thrombus after colon cancer liver metastasis surgery.In order to achieve long-term stability, vNKT cell therapy was chosen and the expected effect was achieved. During this process, vNKT cell immunotherapy plays an indispensable role in reducing the risk of recurrence and metastasis and strengthening the immune system, thereby providing patients with long-term stability.

Reference:< H477>

【1】Baek JH, Kim J, Baek DW, Chang E, Kim HJ, Park SY, Park JS, Choi GS, Kang BW, Kim JG. Clinical Implication of KRAS Mutation Variants in Patients With Resected Colon Cancer. Cancer Diagn Progn. 2022 Jan 3; 2(1):78-83. doi: 10.21873/cdp.10079. PMID: 35399997; PMCID: PMC8962850.

Classic NKT Case Review

Click on the image

You can view

上一篇：结肠癌术后两次复发，抗癌11年，这是他的最新评估报告

下一篇：直肠癌保肛后，平稳迈过第一个五年，他是如何做到的？

About Lehe

New Medical Services

Oncology Clinical Research

Chronic Disease Research

Contact Us

Contact Us

After undergoing surgery and chemotherapy for colon cancer, combined cell therapy has achieved long-term stability

Overview of the disease

Contact Us